Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

BACKGROUND: Posaconazole is effective prophylaxis for invasive fungal infections (IFIs). We compared incidence of breakthrough IFI (bIFI) and early posaconazole discontinuation between patients receiving delayed-release tablet and oral suspension formulations. METHODS: This was a retrospective cohor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Tallman, Gregory B, Furuno, Jon P, Noble, Brie N, Bubalo, Joseph S, Forrest, Graeme N, Lewis, James S, Bienvenida, Ana F, Holmes, Courtney A, Weber, Bo R, McGregor, Jessina C
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631689/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.039
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars